Case Report

Subfulminant Acute Liver Failure by Albendazole: Case Report

Jose Fabio Freirea, c, Lopasso Maria Carolina Rochab, Lopes Gabriel Limae, Pereira Renner Augusto Raposod

Abstract

Acute hepatic failure is a rare and dramatic condition of acute loss of hepatocellular function, generally caused by virus, autoimmune-immunity or drugs, either by idiosyncratic reaction or by dose-dependent injury. We present a case of hepatic injury induced by albendazole, an imidazole derivative, in a patient of 21 years old, who developed acute hepatic failure. She was included at the transplantation list, but had a great clinical evolution, with full recovery of the liver function only with support measures, prescinding of that treatment. In spite of this drug class presents with hepatotoxicity is already widely known fact, there are just few cases in the literature in association with hepatic failure.

Keywords: Hepatotoxicity; Albendazole; Acute liver failure

Introduction

Acute liver failure is a clinical syndrome, potentially reversible, characterized by the emergence of hepatic encephalopathy within 8 weeks after the onset of signs and symptoms of an acute hepatitis, in patients without evidence of chronic hepatic disease [1]. It is a challenging clinical emergency, and it involves a pattern of specific clinical symptoms and pathophysiologic responses. This clinical entity has several forms of liver injury, such as cytotoxic and the cytopathic injuries.

Cytotoxic lesions consists of a direct hepatocellular damage by viruses (except C viruses), drugs, metabolites or toxins; among the most common known associated medications are the analgesics, in particular acetaminophen, antiepileptic, antibiotics, antifungal agents and antihypertensives. On the other hand, the cytopathic injury is mediated by an immune response against the hepatocytes [2].

Acute liver failure is an acute and serious deterioration of hepatocellular function secondary to cytotoxicity, mainly caused by external factors, usually by drugs or even by cholestasis. The current incidence of acute fulminant hepatitis is unknown. There are no data about the incidence of liver failure in Brazil; however, it is known that 2% of liver transplants are made because of acute liver failure [2].

The diagnosis is based on clinical, epidemiological and laboratory findings. The clinical picture is vast, characterized by prodromal symptoms such as nausea, vomiting, low appetite, abdominal discomfort and even by the famous triad, consisting of jaundice, coagulopathy and encephalopathy. Patients usually have dramatic elevations on liver enzyme levels that often exceed 40 times the normality, besides electrolyte changes, coagulation and hematologic tests [3]. These levels do not seem to correlate with prognosis, but the rapid decline of the liver enzyme values, especially more than 60% of their values in 24 h, is a signal of liver failure [4].

Treatment of acute liver failure consists of specific measures of support such as hospitalization in intensive care unit (ICU) and treatment of complications, like infections and bleeding. Importantly, liver transplantation should be considered in patients who have poor prognostic factors, such as serum level of factor V, lactate and activated prothrombin time (PT). The Gc-globulin dosage, vitamin D carrier globulin, has also been associated with prognostic correlation and compared to the King’s College criteria. The use of APACHE criteria is not specific for these patients, but it can be used for evaluation. The MELD score, which is the model score for patients with end-stage liver disease, is useful for patients with chronic hepatocytic failure, but it does not apply for patients with acute liver failure. In this report, we describe a subfulminant acute liver failure in a 21-year-old patient, secondary to the use of albendazole, an antiparasitic drug with few cases described in medical literature with such toxicity [5].
Case Report

TRSO, female, 21-year-old, natural and precedent from Rondonopolis/MT, Brazil, with brown skin, was married, cashier, with one child. Patient presented with nausea and vomiting, accompanied by malaise, mucocutaneous jaundice, dark urine and fecal acholia on October 19, 2011. She had never presented such symptoms.

The patient denied previous personal or familial liver diseases, surgeries, allergies or recent travel and no co-morbidities. As a routine medication, the patient used only oral contraceptive for over 3 years and denied use of acetaminophen (there were no reports of new medication use at the time of the symptoms onset). She denied she had intake teas or herbs in that period.

The patient searched for medical attention in the Hospital Regional de Rondonopolis, where it was identified a cholestatic framework secondary to acute hepatitis; local physicians dosed inflammatory liver markers, canalicular enzymes, bilirubin, coagulation tests and dosage of serum proteins; the results demonstrated laboratory signs of severe hepatocellular injury, as it is shown in Table 1.

The patient evolved with rapid clinical and laboratory worsening in 1 week, with leukocytosis with nuclear left shift (25,400 cells) and hepatic encephalopathy grade III-IV, when it was introduced intravenous ceftriaxone for empirical treatment of infection. She was promptly transferred to the ICU of the Hospital Sao Paulo on October 29, 2011, with an initial diagnosis of fulminant acute hepatitis, for evaluation and priority indication of liver transplantation. The entrance exams in our service are shown in Table 2.

We used only the prognostic score of King’s College (no intake of acetaminophen), because it was not possible to dose the serum factor V to apply the Clichy criteria, as demonstrated in Table 3. As noted, the patient had some criteria of poor prognosis and even sufficient data to indicate a liver transplantation.

In time the patient was in the ICU, she did not present hemodynamic instability, fever, electrolyte disturbances or impaired renal function. We obtained antibodies for autoimmune hepatitis, but all of them were negative.

The patient showed full recovery of the consciousness level and progressive improvement in liver function tests in the first week of hospitalization in our service, when she was transferred to the Women’s Infirmary of Internal Medicine Department on November 5, 2011. The patient began to be accompanied by the gastroenterology and liver transplantation teams.

Gradually the patient improved her cholestatic symptoms and showed normalization of bowel habits, remaining, however, jaundice throughout the hospital stay. We noticed the appearance of papular lesions on the front, chin and back regions (with adjacent xeroderma, scratching signs and crusting), shoulders and upper chest (with several pustular lesions), without signals of secondary infection, similar to those the pa-

### Table 1. Admission Exams From Hospital Regional de Rondonopolis/MT

| ALT: 1,284 | AF: 412 | TB: 19.83 | DB: 9.02 | IB: 10.81 |
| AST: 1,916 | GGT: 33 | Albumin: 3.8 | PT: 18.5% | INR: 6.55 |
| Serology for HAV, HBV, HCV, HIV, toxoplasmosis, CMV, EBV e syphilis: negative |
| Complete coagulation tests e platelets count: normal |
| Ultrasound of the abdomen: normal |

### Table 2. Admission Exams From Hospital Sao Paulo After 10 Days

| CBC: Hb: 13.1; Ht: 38.7; leukocytes: 14,000 cells (0.6/9.2/3.1/20.3/7.1); platelets: 218,000 | ALT: 554 | TB: 20.42 | DB: 19.24 | IB: 1.18 | Albumin: 2.7 |
| Urea: 13 | Creatinine: 0.69 | PT: 35% | INR: 2.27 | aPTT: 1.42 |
| Sodium: 138 | Phosphorus: 3.4 | Magnesium: 1.9 | Potassium: 4.2 | Glucose: 69 |

### Table 3. Liver Transplant Indication Criteria in Acute Liver Failure Without Acetaminophen Intake of King’s College Hospital

1) PT > 100 s or INR > 6.5 (regardless of the encephalopathy degree)
2) Or three of the following variables:
   - Age < 10 or > 40 years old
   - Viral hepatitis (A or B), halothane, pharmacological idiosyncratic reactions
   - Jaundice length > 7 days before the onset of encephalopathy
   - PT > 50 s or INR > 3.5
   - Serum bilirubinemia > 17.5 mg/dL
Liver Failure by Albendazole

Table 4. Evolution of Patient’s Laboratory Tests During Hospitalization From Hospital Sao Paulo

<table>
<thead>
<tr>
<th></th>
<th>August 30, 2011</th>
<th>November 01, 2011</th>
<th>November 04, 2011</th>
<th>November 08, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>410</td>
<td>245</td>
<td>157</td>
<td>115</td>
</tr>
<tr>
<td>AST</td>
<td>150</td>
<td>128</td>
<td>80</td>
<td>95</td>
</tr>
<tr>
<td>Albumin</td>
<td>2.4</td>
<td>2.3</td>
<td>2.7</td>
<td>3.6</td>
</tr>
<tr>
<td>TB</td>
<td>23.03</td>
<td>20.56</td>
<td>20.15</td>
<td>19.20</td>
</tr>
<tr>
<td>IB</td>
<td>4.06</td>
<td>2.77</td>
<td>1.84</td>
<td>9.90</td>
</tr>
<tr>
<td>DB</td>
<td>18.97</td>
<td>17.79</td>
<td>18.31</td>
<td>9.30</td>
</tr>
<tr>
<td>PT</td>
<td>34%</td>
<td>42%</td>
<td>64%</td>
<td>87%</td>
</tr>
<tr>
<td>INR</td>
<td>2.34</td>
<td>1.92</td>
<td>1.36</td>
<td>1.09</td>
</tr>
<tr>
<td>Urea</td>
<td>09</td>
<td>29</td>
<td>17</td>
<td>20</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.73</td>
<td>1.03</td>
<td>0.95</td>
<td>0.82</td>
</tr>
<tr>
<td>Glucose</td>
<td>95</td>
<td>74</td>
<td>101</td>
<td>90</td>
</tr>
</tbody>
</table>

Discussion

Liver injury-induced by drugs (LIID) is a well-documented condition in the scientific environment and its annual incidence in patients with prescribed medication is around 1 in 10,000 - 100,000 exposed people [6]. It accounts for about 10% of adverse drug reactions [7].

The LIID is part of the differential diagnosis of liver diseases, and this hypothesis must be strengthened in the exclusion of other etiological factors associated with clinical history. Its presentation spectrum is broad, ranging from small laboratory changes to liver failure. Idiosyncratic LIID with acetaminophen intoxication is the major cause of acute liver failure in the United States and Sweden. It is also the leading cause of withdrawal of drugs that are already in clinical use [8, 9]. We have no accurate epidemiological data in Brazil.

Hepatotoxicity by drugs may occur secondary to two mechanisms: direct or idiosyncratic hepatocellular injury. Direct hepatotoxicity may be predictable, since it is dose-dependent and it has a short time between the exposure and the onset of symptoms. The idiosyncratic agents do not have predictable toxicity or dose-dependence [8].

Liver injury triggered by albendazole is relatively common, including mild-to-moderate changes in liver enzymes, reported in approximately 16% of patients using this medication [10]. However, liver failure secondary to the use of albendazole is extremely rare, with few reported cases in medical literature [11, 12]. We did not find case reports of fulminant hepatic failure.

The diagnosis of drug-induced liver injury is a challenge that can be obtained through three methods: 1) expert opinion; 2) probabilistic approach; or 3) using diagnostic scales. The diagnostic scale of the Council for International Organizations of Medical Sciences (CIOMS), also known as the causal Assessment Method or RUCAM, although complex and difficult to apply by doctors who are unfamiliar with induced liver injury by drugs, is often used by hepatologists [13].

In our case, applying the CIOMS or the RUCAM scale, a probable association between the consumption of medication and adverse drug reaction was obtained. The possible score results with these scales are: unlikely (1 - 2 points), possible (3 - 4 points), probable (5 - 8 points) and highly likely (> 8 points). The time relationship between the drug and the onset of the symptoms is very suggestive, and in addition, other secondary
causes of hepatitis were investigated, including viral hepatitis, autoimmune hepatitis among others, and all were excluded.

The remarkable thing in this case is the unfavorable outcome of the drug-induced hepatitis, evolving with subfulminant liver failure. The patient was listed and prioritized for liver transplantation; however, she developed spontaneous improvement of the liver failure only with supportive measures, before the organ donation was achieved.

Other cases of acute hepatitis secondary to use of albendazole have been reported in the literature, however, presenting with a more benign evolution. The treatment of hepatic echinococcosis with albendazole was reported in two previous studies: the first one coursing with jaundice in only one case report [7], and in the second article with the appearance of hepatocellular failure in seven patients in a case series of 40 patients during the treatment with the imidazole. This condition, however, often requires longer treatment with albendazole [8].

In Brazil, the use of antiparasitic agents is very common, both as a treatment for intestinal parasites and also for prophylaxis, often without medical prescription due to the ease of public access to the drug. Based on the occurrence of some cases already reported in the literature, the investigation of liver disease should include the research of albendazole use and other imidazoles during the anmnesis. This theme also deserves further study to better understand the pathophysiology related to the hepatotoxicity of this agent.

References